CN101422479A - Compound injection medicine composite for treating pig, cattle respiratory disease - Google Patents
Compound injection medicine composite for treating pig, cattle respiratory disease Download PDFInfo
- Publication number
- CN101422479A CN101422479A CNA200810126482XA CN200810126482A CN101422479A CN 101422479 A CN101422479 A CN 101422479A CN A200810126482X A CNA200810126482X A CN A200810126482XA CN 200810126482 A CN200810126482 A CN 200810126482A CN 101422479 A CN101422479 A CN 101422479A
- Authority
- CN
- China
- Prior art keywords
- acid
- mycin
- thailand
- sodium
- flunixin
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
The invention relates to a compound injection medicament compound for curing the respiratory diseases of animals, in particular to a compound injection medicament compound which is used for curing the respiratory diseases of pigs and cows and contains tara zymoid and non-steroidal analgesics of effective amount.
Description
Technical field:
The present invention relates to a kind of compound injection medicine composite for the treatment of the animal breath tract disease, particularly a kind of compound injection medicine composite that is used for the treatment of pig, cattle respiratory disease.
Background technology:
Respiratory tract disease is one of infectious disease more rambunctious in the animal husbandry, and serious to animal husbandry harm, the economic loss that worldwide causes is huge, China annual because of raising pigs of causing of respiratory tract disease and cattle-raising with a toll of hundreds billion of units.The economic loss that causes mainly is because respiratory tract disease causes the death of animal easily, loses weight, and milk yield descends, and the reduction of huge medical expense and feeding efficiency.
The porcine respiratory disease also is porcine respiratory disease syndrome (Swine respiratory disease complex, SRDC), be a kind of general name of the multifactor respiratory tract disease that causes, it is interacted by virus, antibacterial, environmental stress and pig body hypoimmunity and causes.The main source of disease of bacterial respiratory tract disease syndrome is killing property Pasteurellas, pig hemophilus disease, pig bordetella bacilli disease, actinobacillus suis pleuropneumonia, streptococcus, Salmonella choleraesuis, mycoplasma etc. more.The viral respiratory disease syndrome is mainly caused by porcine reproductive and respiratory syndrome virus (PRRSV), porcine pseudorabies virus (PRV), swine influenza virus (SIV), PRCV (Porcine Respiratory Coronavirus) (PRCV) and pig circular ring virus (PCV) etc.
The respiratory tract disease of cattle (BRD) is also referred to as cattle respiratory disease syndrome (BRDC), and is very similar to the porcine respiratory disease, also is to be caused by reasons such as environment, physiological stress, antibacterial and viruses.Hemolytic Man bacillus, kill the main cause that property Pasteurella, Haemophilus somnus etc. are considered to cause the cattle upper respiratory tract disease more, and when environmental factors and physiological stress reduce self-resistance and suppressed the defensive enginery of pulmonary, these antibacterials will increase sharply and growth in lower respiratory tract portion, and multiple in addition bovine viral such as infectious bovine rhinotrachetis virus (IBRV), bovine diarrhea virus (BVDV), respiratory syncytial virus (BRSV), parainfluenza virus-3 (PI-3) have the immunosuppressant effect to the pulmonary of cattle.
Because the release that antibacterial stimulates lung inflammation to be produced a large amount of toxin and then promote various cytokines, this more impels inflammation to take place.Hemolytic Man bacillus is considered to the most deleterious pathogenic bacteria, and produces leukocidin, and it passes through to suppress the leukocyte phagocytosis, and then has more promoted the bacterial reproduction in lower respiratory tract portion.This process usually causes the generation of bacterial tracheitis.
It is because the excessive inflammatory response of invasion pathogenic bacteria is caused that pulmonary damages the death cause, is owing to the natural killer cell of neutrophilic granulocyte, pulmonary alveolar macrophage and destruction infection cell occurred to the infringement of host tissue.When cell membrane was destroyed, arachidonic acid was released.Arachidonic acid is the substrate that various prostaglandins and other eicosane olefin(e) acid form, and the release of these bioactive substances is vital to the inflammatory reaction that causes pulmonary lesion.
The pulmonary lesion that the pathogeny of respiratory complication is included in the tangible inflammatory process of pulmonary and causes then, and usually cause lung fibrosis.Whether inflammation degree decision ill domestic animal can cause death still is returning to one's perfect health of chronic respiratory tract disease or animal.Various antiinflammatories also according to the ability of the treatment symptom relevant with respiratory complication has been carried out research as: cooling, reduce the effect of lung fibrosis and body weight reduction.
The treatment respiratory complication must reach following purpose: can the inflammation of quick control animal lung worsen, and the scheme that first-selection takes place that controls inflammation is exactly bacterium breeding of control source of disease and the heating inflammation Signs of controlling the animal that is caused by the breeding of source of disease bacterium simultaneously, eliminate the heating inflammatory symptom and help animal increase feed intake, improve autoimmunity, and then recover health.
Corticosteroid is owing to can cause that serious immunosuppressive action is limited to be used for the treatment of respiratory tract disease usually, and NSAID (non-steroidal anti-inflammatory drug) and antibiotic coupling have shown that the respiratory tract disease to treatment cattle, pig is effective.It is effectively that NSAID (non-steroidal anti-inflammatory drug) such as flunixin meglumine, meloxicam, ketoprofen, tolfenamic acid and carprofen etc. have been proved reducing the heating relevant with respiratory tract fast, and can reduce lung fibrosis and the needs that reduce with the antibiotic repetitive therapy.
The invention provides a kind of compound injection medicine composite for the treatment of the animal breath tract disease, particularly a kind of compound injection medicine composite that is used for the treatment of pig, cattle respiratory disease.
Describe from the compound injection medicine composite of following two aspects this invention:
1. the compositions of Xing Chenging is quality controllable and stable in production and storage process;
2. drug combination must reach the control infection pathogen and reduce heating, the pain symptom that animal causes because of lung inflammation fast
Eliminate pneumonia simultaneously, make animal increase feed intake, improve autoimmunity, make physical recovery.
We discover that Thailand draws the use of mycin (Tulathromyin), azithromycin (Azithromycin), Ketek (Telithromycin), these medicines of clarithromycin (Clarithromycin) and NSAID (non-steroidal anti-inflammatory drug) compound preparation to achieve the above object based on above-mentioned these two purposes.Antibiotic first-selected in the antibiotic composition of these compounds is that mycin draws in Thailand.It is a kind of Macrolide semisynthetic antibiotics of up-to-date animal specific that mycin (Tulathromyin) draws in Thailand, because it has good antibacterial activity, with be better than other antibiotic overlength half-life (approximately 90h), it can keep for a long time effectively treatment concentration in vivo, only need a low dosage administration, can keep effective treatment concentration of 5-7 days in animal body.Numerous clinical efficacy experimental study results shows that Thailand draws mycin (Tulathromyin) that the therapeutic effect of pig and cattle respiratory system is better than medicines such as florfenicol, tilmicosin, ceftiofur and enrofloxacin, the therapeutic effect that has for the respiratory tract disease of cattle and pig.
Non-steroidal analgesic-antipyretic comprises flunixin, aspirin, diflunisal, indomethacin, Ah former times is U.S. hot, cinmetacin, the fragrant acid of single (two) chlorine, tiaprofenic acid, the vinegar ketoprofen acid, first Luo Fenna acid, mefenamic acid, chlorine Fen Namin, fluorine Fen Namin, tolfenamic acid, the Yi Luofenna ester, floctafenine, sulindac; bufexamac; clidanac; Tolmetin; ketorolac; naproxen; ibuprofen; ketoprofen; fenbufen; pirprofen; alminoprofen; flurbiprofen; carprofen; fenoprofen; loxoprofen; oxaprozin; pyrrole Luo Xikang; meloxicam; lornoxicam; celecoxib; rofecoxib; nimesulide; dipyrone; Phenylbutazone; oxyphenbutazone; epirizole; benzydamine; feprazone; nabumetone; leflunomide; sinomenine; fentanyl; rotundine; Ergotamine; bucinnazine etc. and their derivant and salt.
Wherein flunixin meglumine is the inhibitor of Cycloxygenase, by suppressing the Cycloxygenase in the arachidonic acid reaction chain, reduce the generation of inflammatory mediators such as prostaglandin and thromboxane, by keeping the normal blood osmotic pressure, alleviate injury of vascular endothelial cells, keeping approach such as normal blood volume, stop that escherichia coli endotoxin causes that exudate increases in the bronchus in the respiratory tract disease, number of ways such as neutrophil cell, albumin gathering in the exudate, effectively alleviate organism fever, inflammation and pain.The adjuvant therapy medicaments that is used for pig, cows respiratory tract disease.
The drug combination of existing antibiotic and flunixin meglumine has the compound formulation of oxytetracycline or florfenicol and flunixin meglumine on the market, but because the increase big and service time of the using dosage of these medicines has produced food-safety problem and drug resistance, and therapeutic effect also seriously reduces, and Thailand draws the drug combination of mycin (Tulathromyin) and flunixin meglumine not report.
Summary of the invention:
The invention provides a kind of compound injection medicine composite for the treatment of the animal breath tract disease, it is characterized in that, mycin and nonsteroidal antipyretic analgesic draw in the Thailand of containing effective dose.
Compositions provided by the invention, it is wherein safe that to draw mycin be the complex that mycin A and Tai La mycin B draw in Thailand, both part by weight are 85～96:15～4; The nonsteroidal antipyretic analgesic comprises flunixin, aspirin, diflunisal, indomethacin, Ah former times is U.S. hot, cinmetacin, diclofenac, tiaprofenic acid, the vinegar ketoprofen acid, first Luo Fenna acid, mefenamic acid, tolfenamic acid, chlorine Fen Namin, fluorine Fen Namin, the Yi Luofenna ester, floctafenine, sulindac; bufexamac; clidanac; Tolmetin; ketorolac; naproxen; ibuprofen; ketoprofen; fenbufen; pirprofen; alminoprofen; flurbiprofen; carprofen; fenoprofen; loxoprofen; oxaprozin; pyrrole Luo Xikang; meloxicam; lornoxicam; celecoxib; rofecoxib; nimesulide; dipyrone; Phenylbutazone; oxyphenbutazone; epirizole; benzydamine; feprazone; nabumetone; leflunomide; sinomenine; fentanyl; rotundine; Ergotamine; bucinnazine; and their derivant or salt; wherein active component is a flunixin, or its salt flunixin meglumine.
Contain the medicine acceptable carrier in the compositions provided by the invention, comprise solvent, antioxidant, chelating agent, stabilizing agent, wherein solvent is water or organic solvent or their mixture, wherein organic solvent is: 2-Pyrrolidone, N, the N-dimethyl pyrrolidone, the N-N-methyl-2-2-pyrrolidone N-, Polyethylene Glycol, propylene glycol, ethanol, glycerol, isopropyl alcohol, dimethyl formamide, dimethyl acetylamide, dimethyl sulfoxide, glycerol formal, glyceryl triacetate, tween or span, antioxidant wherein is a sulphite, sodium sulfite, sodium pyrosulfite, formaldehyde closes sodium sulfite, sodium thiosulfate, sodium dithionite, 2-hydroxy-2-propane-sulfonic acid sodium salt, hydroxyl Loprazolam sodium, L one vitamin C, D one vitamin C, vitamin C palm fibre eleostearate, the red bright alcohol of dithio, dithiothreitol dithio, thioglycerol, thiourea, 2 one mercaptoethanols, 3 one mercaprols, dimercaptopropanol, BAL, 1 monothio sorbitol, 5 monothios, one D, one glucose, TGA, thiacetic acid., 2-mercaptopropionic acid, mercaptosuccinic acid., α one mercaptopropionic acid glycine, 3 monothio dipropionic acids, hydroquinone, tocopherol, propyl gallate, just two hydrogen guaiacol, butylated hydroxyarisol, the dibutyl cresols; Chelating agent is sodium ethylene diamine tetracetate, EDTA calcium complex disodium salt, 1,2 one 1,2-diaminocyclohexane tetraacetic acid, diethylenetriamine pentaacetic acid, N one (2 one an ethoxy) ethylenediamine triacetic acid trisodium salt, N one or two (2 one ethoxy) glycine or boric acid; Stabilizing agent is mineral acid or organic acid, and wherein mineral acid or organic acid are hydrochloric acid, dilute sulfuric acid, nitric acid, phosphoric acid, citric acid, tartaric acid, acetic acid or trifluoroacetic acid.
Compositions provided by the invention, be the injecting fluid form, flunixin meglumine is dissolvable in water in the water and makes stable aqueous solution, mycin (Tulathromyin) draws in Thailand though the original shape medicine is insoluble in water, but under acid condition in the water soluble, so the solvent of this compound formulation is mainly distilled water.The ratio of water in said preparation is 5～90%.
Except that main solvent carrier, in the injectable pharmaceutical compositions of this invention, also must add suitable stabilizing agent, chelating agent, antioxidant and antiseptic.The double antiseptic of doing in this invention component of thioglycerol wherein, consumption is respectively 0.5% and 0.1%.
Injecting fluid pharmaceutical composition provided by the invention, it is wherein safe that to draw the content of mycin be 10～350mg/ml, the content of flunixin or its salt is 1～350mg/ml.Preferably safe to draw the content of mycin be 20～100mg/ml, and the content of flunixin or its salt is 20～100mg/ml, and it is 40～70mg/ml that the content of mycin draws in preferred Thailand, and the content of flunixin or its salt is 30～60mg/ml.
Composite formula of the present invention, wherein safe weight ratio of drawing mycin and flunixin, preferably 50mg/ml is than the 25mg/ml ratio of (being equivalent to flunixin meglumine 41.5mg/ml).
The most preferred prescription of injectable pharmaceutical compositions of the present invention consists of:
Contain among the 100ml:
Mycin (tulathromycin): 5.0g draws in Thailand
Flunixin meglumine: 4.15g
Citric acid: 0.15g
Thioglycerol: 0.5g
TGA: 0.1g
Sodium ethylene diamine tetracetate: 0.5g
Water for injection is extremely: 100ml
Transfer PH to 4.5～5.5
Preparation of drug combination method of the present invention:
In the 200ml beaker, add 80ml water for injection, add Thailand and draw mycin (tulathromycin), stir and add citric acid to dissolving, add thioglycerol, TGA and a small amount of dissolved sodium ethylene diamine tetracetate of water for injection successively, transferring PH with HCL or NaOH solution is 4.5～5.5, is settled to scale with water for injection.Gained solution is colourless to light yellow clear and bright solution.
Below be comparative experiments research:
Pharmaceutical composition of the present invention (rhzomorph-flunixin meglumine injection compound medicament composition draws in Thailand): A liquid: rhzomorph-flunixin meglumine compound injection medicine composite component is drawn by Thailand:
Contain among the 100ml:
Mycin (tulathromycin): 5.0g draws in Thailand
Flunixin meglumine: 4.15g
Citric acid: 0.15g
Thioglycerol: 0.5g
TGA: 0.1g
Sodium ethylene diamine tetracetate: 0.5g
Water for injection is extremely: 100ml
It is 4.5～5.5 that HCL or NaOH solution are transferred PH
Preparation process:
In the 200ml beaker, add 80ml water for injection, add Thailand and draw mycin (tulathromycin), stir and add citric acid to dissolving, add thioglycerol, TGA and a small amount of dissolved sodium ethylene diamine tetracetate of water for injection successively, transferring PH with HCL or NaOH solution is 4.5～5.5, is settled to scale with water for injection.Gained solution is colourless to light yellow clear and bright solution.
B liquid: mycin (tulthromycin) injection draws in Thailand
Mycin (tulthromycin): 5g draws in Thailand
Citric acid: 0.10g
Thioglycerol: 0.5g
TGA: 0.1g
Sodium ethylene diamine tetracetate: 0.5g
Water for injection is extremely: 100ml
It is 4.5～5.5 that HCL or NaOH solution are transferred PH
Preparation process is with A liquid.
C liquid: flunixin meglumine inj
Flunixin meglumine: 4.15g
Citric acid: 0.10g
Thioglycerol: 0.5g
TGA: 0.1g
Sodium ethylene diamine tetracetate: 0.5g
Water for injection is extremely: 100ml
It is 4.5～5.5 that HCL or NaOH solution are transferred PH
Preparation process is with A liquid.
Experiment is compared:
Draw mycin-flunixin meglumine compound injection medicine composite and individually dosed Thailand to draw the drug effect of mycin injection, flunixin meglumine inj to compare to administered intramuscular Thailand:
Get about 24 body weight 20kg and typical secondary haemophilus disease symptoms is arranged and be the male and female pig half and half that astasia is decided state, be divided into 4 groups, every group 6, each 3 of male and females, drug administration by injection A, B, C liquid are three groups of administration groups respectively, and in A, B, C, establishing not administration group is matched group, dosage draws mycin and 2.08mg/kgBW flunixin meglumine by 2.5mg/kgBW Thailand, and the A group is administered once; The B group is administered once; C group administration 2 times/day, logotype medicine 3 days.
1) body temperature changes: after administration 0,0.5,1,2,3,4,6,8,10,12,24,36, measured rectal temperature in 48,72 hours, write down every group body temperature meansigma methods, the results are shown in Table 1.
2) clinical symptoms: regularly also writing down the clinical symptoms of pig every day, is foundation with the situation of searching for food, the mental status, breathing, cough and nose secretion mucus degree, is divided into four grade scorings by the order of severity of state, the 0-normal condition, 1-is slight, the 2-moderate, 3-is more serious, and 4-is serious.The results are shown in following table 2.
3) pathology detection: pulmonary's swelling, congestion, hemorrhage, thoracic cavity have that serosity oozes out, adhesion, thoracic cavity, peritoneum inflammation, pericarditis and fibrosis.
4) body weight change situation: from administration after 7 days weighing respectively organize pig body weight change situation, record meansigma methods, the results are shown in Table 3.
Table 1 body temperature situation of change
Numeral is the survival number in ()
Table 2 clinical symptoms is divided the result equally by grade
Numeral is the survival number in ()
Table 3 death and body weight change situation
Conclusion:
1, have only administration Thailand to draw mycin-flunixin meglumine compound injection medicine composite as can be seen from Table 1, heating and inflammation can disappear simultaneously, the also fast quick-recovery of the health of pig.And administration Thailand draws the oligomict pig of mycin injection to recover slower, and the oligomict temperature of pig body of administration flunixin meglumine inj occurs repeatedly, illustrates that inflammation do not eliminate, and can not return to one's perfect health.
2, administration Thailand draws the 4th day all clinical symptoms of pig of mycin-flunixin meglumine compound injection medicine composite to disappear substantially as can be seen from Table 2; And administration Thailand draws the 7th day clinical condition of the oligomict pig of mycin injection just to disappear, physical rehabilitation; The 7th day symptom of the oligomict pig of administration flunixin meglumine inj is still relatively more serious.
Though 3, give the pig of A, B, three kinds of medicines of C all not dead as can be seen from Table 3, but the gain in weight maximum that the pig of mycin-flunixin meglumine compound injection medicine composite is drawn by administration Thailand in weightening finish, administration Thailand drew the effect of mycin-flunixin meglumine compound injection medicine composite to be better than administration Thailand and draws mycin list composition or the oligomict therapeutic effect of administration flunixin meglumine when the respiratory tract disease for the treatment of pig was described.
The specific embodiment:
Further specify the present invention by the following examples, but not as limitation of the present invention.
Embodiment 1
Rhzomorph-flunixin meglumine compound injection medicine composite component is drawn by Thailand:
Contain among the 100ml:
Mycin (tulathromycin): 5.0g draws in Thailand
Flunixin meglumine: 4.15g
Citric acid: 0.15g
Thioglycerol: 0.5g
TGA: 0.1g
Sodium ethylene diamine tetracetate: 0.5g
Water for injection is extremely: 100ml
It is 4.5～5.5 that HCL or NaOH solution are transferred PH
Preparation process:
In the 200ml beaker, add 80ml water for injection, add Thailand and draw mycin (tulathromycin), stir and add citric acid to dissolving, add thioglycerol, TGA and a small amount of dissolved sodium ethylene diamine tetracetate of water for injection successively, transferring PH with HCL or NaOH solution is 4.5～5.5, is settled to scale with water for injection.Gained solution is colourless to light yellow clear and bright solution.
Embodiment 2
Rhzomorph-flunixin meglumine compound injection medicine composite draws in Thailand:
Contain among the 100ml:
Mycin (tulathromycin): 1.0g draws in Thailand
Flunixin meglumine: 0.83g
Citric acid: 0.15g
Thioglycerol: 0.5g
TGA: 0.1g
Sodium ethylene diamine tetracetate: 0.5g
Water for injection is extremely: 100ml
It is 4.5～5.5 that HCL or NaOH solution are transferred PH
Embodiment 3
Rhzomorph-flunixin meglumine compound injection medicine composite draws in Thailand:
Contain among the 100ml:
Mycin (tulathromycin): 35.0g draws in Thailand
Flunixin meglumine: 29.05g
Citric acid: 0.15g
Thioglycerol: 0.5g
TGA: 0.1g
Sodium ethylene diamine tetracetate: 0.5g
Water for injection is extremely: 100ml
It is 4.5～5.5 that HCL or NaOH solution are transferred PH
Embodiment 4
Rhzomorph-flunixin meglumine compound injection medicine composite draws in Thailand:
Contain among the 100ml:
Mycin (tulathromycin): 5.0g draws in Thailand
Flunixin: 2.5g
Citric acid: 0.15g
Thioglycerol: 0.5g
TGA: 0.1g
Sodium ethylene diamine tetracetate: 0.5g
Water for injection is extremely: 100ml
It is 4.5～5.5 that HCL or NaOH solution are transferred PH
Preparation process:
Embodiment 5
Rhzomorph-flunixin meglumine compound oral pharmaceutical composition draws in Thailand:
Contain among the 100ml:
Mycin (tulathromycin): 2.0g draws in Thailand
Flunixin meglumine: 3g
Citric acid: 0.15g
Thioglycerol: 0.5g
TGA: 0.1g
Sodium ethylene diamine tetracetate: 0.5g
Water for injection is extremely: 100ml
It is 4.5～5.5 that HCL or NaOH solution are transferred PH
Embodiment 6
Rhzomorph-flunixin meglumine compound injection medicine composite draws in Thailand:
Contain among the 100ml:
Mycin (tulathromycin): 7.0g draws in Thailand
Flunixin meglumine: 6g
Citric acid: 0.15g
Thioglycerol: 0.5g
TGA: 0.1g
Sodium ethylene diamine tetracetate: 0.5g
Water for injection is extremely: 100ml
It is 4.5～5.5 that HCL or NaOH solution are transferred PH
Embodiment 7
Rhzomorph-flunixin meglumine compound injection medicine composite draws in Thailand:
Contain among the 100ml:
Mycin (tulathromycin): 5.0g draws in Thailand
Flunixin meglumine: 4.15g
Hydrochloric acid: 0.15g
Sodium sulfite: 0.5g
TGA: 0.1g
Calcio-disodium edetate: 0.5g
Water for injection is extremely: 100ml
It is 4.5～5.5 that HCL or NaOH solution are transferred PH
Claims (10)
1, a kind of compound injection medicine composite for the treatment of the animal breath tract disease is characterized in that, mycin and nonsteroidal antipyretic analgesic draw in the Thailand of containing effective dose.
2, compositions according to claim 1, wherein the nonsteroidal antipyretic analgesic comprises flunixin, aspirin, diflunisal, indomethacin, Ah former times is U.S. hot, cinmetacin, diclofenac, tiaprofenic acid, the vinegar ketoprofen acid, first Luo Fenna acid, mefenamic acid, tolfenamic acid, chlorine Fen Namin, fluorine Fen Namin, the Yi Luofenna ester, floctafenine, sulindac; bufexamac; clidanac; Tolmetin; ketorolac; naproxen; ibuprofen; ketoprofen; fenbufen; pirprofen; alminoprofen; flurbiprofen; carprofen; fenoprofen; loxoprofen; oxaprozin; pyrrole Luo Xikang; meloxicam; lornoxicam; celecoxib; rofecoxib; nimesulide; dipyrone; Phenylbutazone; oxyphenbutazone; epirizole; benzydamine; feprazone; nabumetone; leflunomide; sinomenine; fentanyl; rotundine; Ergotamine; bucinnazine; and their derivant or salt
3, compositions according to claim 1, wherein active ingredient is that mycin and flunixin draw in Thailand, or mycin and flunixin meglumine draw in Thailand.
4, compositions according to claim 3 wherein also contains the medicine acceptable carrier.
5, compositions according to claim 3 is the liquid oral form, and wherein safe to draw the content of mycin be 10～350mg/ml, and the content of flunixin or its salt is 1～350mg/ml.
6, compositions according to claim 5, it is wherein safe that to draw the content of mycin be 20～100mg/ml, the content of flunixin or its salt is 20～100mg/ml.
7, compositions according to claim 5, described medicine acceptable carrier, comprise solvent, antioxidant, chelating agent, stabilizing agent, wherein solvent is water or organic solvent or their mixture, wherein organic solvent is: 2-Pyrrolidone, N, the N-dimethyl pyrrolidone, the N-N-methyl-2-2-pyrrolidone N-, Polyethylene Glycol, propylene glycol, ethanol, glycerol, isopropyl alcohol, dimethyl formamide, dimethyl acetylamide, dimethyl sulfoxide, glycerol formal, glyceryl triacetate, tween or span, antioxidant wherein is a sulphite, sodium sulfite, sodium pyrosulfite, formaldehyde closes sodium sulfite, sodium thiosulfate, sodium dithionite, 2-hydroxy-2-propane-sulfonic acid sodium salt, hydroxyl Loprazolam sodium, L one vitamin C, D one vitamin C, vitamin C palm fibre eleostearate, the red bright alcohol of dithio, dithiothreitol dithio, thioglycerol, thiourea, 2 one mercaptoethanols, 3 one mercaprols, dimercaptopropanol, BAL, 1 monothio sorbitol, 5 monothios, one D, one glucose, TGA, thiacetic acid., 2-mercaptopropionic acid, mercaptosuccinic acid., α one mercaptopropionic acid glycine, 3 monothio dipropionic acids, hydroquinone, tocopherol, propyl gallate, just two hydrogen guaiacol, butylated hydroxyarisol, the dibutyl cresols; Chelating agent is sodium ethylene diamine tetracetate, EDTA calcium complex disodium salt, 1,2 one 1,2-diaminocyclohexane tetraacetic acid, diethylenetriamine pentaacetic acid, N one (2 one an ethoxy) ethylenediamine triacetic acid trisodium salt, N one or two (2 one ethoxy) glycine or boric acid; Stabilizing agent is hydrochloric acid, dilute sulfuric acid, nitric acid, phosphoric acid, citric acid, tartaric acid, acetic acid or trifluoroacetic acid.
8, according to the compositions of claim 7, prescription consists of:
Contain among the 100ml:
Mycin draws in Thailand: 2-10g
Flunixin meglumine: 2-10g
Citric acid: 0.15g
Thioglycerol: 0.5g
TGA: 0.1g
Sodium ethylene diamine tetracetate: 0.5g
Water for injection is extremely: 100ml
Transferring PH is 4.5～5.5.
9, according to the compositions of claim 1, prescription consists of:
Contain among the 100ml:
Mycin draws in Thailand: 5.0g
Flunixin meglumine: 4.15g
Citric acid: 0.15g
Thioglycerol: 0.5g
TGA: 0.1g
Sodium ethylene diamine tetracetate: 0.5g
Water for injection is extremely: 100ml
Transferring PH is 4.5～5.5.
10, according to the preparation of compositions method of claim 9: step is as follows:
In the 200ml beaker, add 80ml water for injection, add Thailand and draw mycin, flunixin meglumine, stir and add citric acid to dissolving, the sodium ethylene diamine tetracetate that adds thioglycerol, TGA and a small amount of dissolved in distilled water successively, transferring PH with HCL or NaOH solution is 4.5～5.5, is settled to scale with distilled water, and gained solution is colourless to light yellow clear and bright solution.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNA200810126482XA CN101422479A (en) | 2008-07-04 | 2008-07-04 | Compound injection medicine composite for treating pig, cattle respiratory disease |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNA200810126482XA CN101422479A (en) | 2008-07-04 | 2008-07-04 | Compound injection medicine composite for treating pig, cattle respiratory disease |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN101422479A true CN101422479A (en) | 2009-05-06 |
Family
ID=40613508
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CNA200810126482XA Pending CN101422479A (en) | 2008-07-04 | 2008-07-04 | Compound injection medicine composite for treating pig, cattle respiratory disease |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN101422479A (en) |
Cited By (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101548945B (en) * | 2009-05-27 | 2010-11-10 | 韶山大北农动物药业有限公司 | Long-acting flunixin meglumine injection and method for preparing same |
| CN102166224A (en) * | 2010-12-10 | 2011-08-31 | 上海恒丰强动物药业有限公司 | Antibiotic mate for treating colibacillosis and preparation method thereof |
| CN102793700A (en) * | 2012-08-29 | 2012-11-28 | 郑州后羿制药有限公司 | Compound oil emulsion injection containing flumequine and preparation method thereof |
| CN102908311A (en) * | 2012-11-02 | 2013-02-06 | 青岛农业大学 | Tolfenamic acid injection and preparation method and application thereof |
| CN104725446A (en) * | 2015-03-26 | 2015-06-24 | 宁夏泰瑞制药股份有限公司 | Method for separating tulathromycin A and tulathromycin B from tulathromycin coarse product |
| CN108478576A (en) * | 2018-05-21 | 2018-09-04 | 任铁燕 | A kind of citric acid rotundin injection and preparation method thereof |
| CN109806273A (en) * | 2019-03-05 | 2019-05-28 | 艾美科健（中国）生物医药有限公司 | Tulathromycin and the composite solution agent of Gamithromycin and the preparation method and application thereof |
| CN111603475A (en) * | 2020-05-27 | 2020-09-01 | 华南农业大学 | Long-acting compound tylonolide injection and preparation method thereof |
| WO2022025831A1 (en) * | 2020-07-26 | 2022-02-03 | Verano Ilac Sanayi Ve Ticaret Anonim Sirketi | Pharmaceutical compositions for injection comprising tulathromycin |
-
2008
- 2008-07-04 CN CNA200810126482XA patent/CN101422479A/en active Pending
Cited By (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101548945B (en) * | 2009-05-27 | 2010-11-10 | 韶山大北农动物药业有限公司 | Long-acting flunixin meglumine injection and method for preparing same |
| CN102166224A (en) * | 2010-12-10 | 2011-08-31 | 上海恒丰强动物药业有限公司 | Antibiotic mate for treating colibacillosis and preparation method thereof |
| CN102793700B (en) * | 2012-08-29 | 2014-03-12 | 郑州后羿制药有限公司 | Compound oil emulsion injection containing flumequine and preparation method thereof |
| CN102793700A (en) * | 2012-08-29 | 2012-11-28 | 郑州后羿制药有限公司 | Compound oil emulsion injection containing flumequine and preparation method thereof |
| CN102908311B (en) * | 2012-11-02 | 2015-07-15 | 青岛农业大学 | Tolfenamic acid injection and preparation method and application thereof |
| CN102908311A (en) * | 2012-11-02 | 2013-02-06 | 青岛农业大学 | Tolfenamic acid injection and preparation method and application thereof |
| CN104725446A (en) * | 2015-03-26 | 2015-06-24 | 宁夏泰瑞制药股份有限公司 | Method for separating tulathromycin A and tulathromycin B from tulathromycin coarse product |
| CN104725446B (en) * | 2015-03-26 | 2017-10-27 | 宁夏泰瑞制药股份有限公司 | A kind of method that Tulathromycin A and Tulathromycin B is separated in the crude product from Tulathromycin |
| CN108478576A (en) * | 2018-05-21 | 2018-09-04 | 任铁燕 | A kind of citric acid rotundin injection and preparation method thereof |
| CN109806273A (en) * | 2019-03-05 | 2019-05-28 | 艾美科健（中国）生物医药有限公司 | Tulathromycin and the composite solution agent of Gamithromycin and the preparation method and application thereof |
| CN111603475A (en) * | 2020-05-27 | 2020-09-01 | 华南农业大学 | Long-acting compound tylonolide injection and preparation method thereof |
| CN111603475B (en) * | 2020-05-27 | 2021-01-29 | 华南农业大学 | Long-acting compound tylonolide injection and preparation method thereof |
| WO2022025831A1 (en) * | 2020-07-26 | 2022-02-03 | Verano Ilac Sanayi Ve Ticaret Anonim Sirketi | Pharmaceutical compositions for injection comprising tulathromycin |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN101461821B (en) | Compound oral medicament composition for treating respiratory diseases of pig and cattle | |
| CN101422479A (en) | Compound injection medicine composite for treating pig, cattle respiratory disease | |
| CN101836952B (en) | Ambroxol injection and preparation method thereof | |
| CN101810627B (en) | Compound sulfamonomethoxine/compound sulfamonomethoxine sodium injection and preparation method | |
| EP1462101B1 (en) | Drinkable preparation comprising ketoprofen and use thereof in the simultaneous treatment of a group of animals of respiratory diseases | |
| CN101548945B (en) | Long-acting flunixin meglumine injection and method for preparing same | |
| CN114469930A (en) | Application of aristolochic acid IVa in preparing antihistaminic or pneumonia treatment medicine | |
| US20110144048A1 (en) | Novel Uses of Neuraminidase Inhibitors in Infectious Diseasess | |
| CN102861100A (en) | Compound injection for treating animal respiratory tracts and preparation method thereof | |
| RU2464979C1 (en) | Medicine for treatment and prevention of postnatal endometritis and syndrome of metritis-mastitis-agalactia in sows | |
| ES2281136T3 (en) | USE OF 9A-AZALIDOS AS VETERINARY ANTIMICROBIAL AGENTS. | |
| CN104983686A (en) | Meloxicam soluble powder for livestock and poultry and preparation method thereof | |
| CN103169652B (en) | Veterinary alkaline lincomycin injection as well as preparation method and use thereof | |
| PT1510214E (en) | 8a-azalides as veterinary antimicrobial agents | |
| CN111568861A (en) | Bromhexine hydrochloride oral liquid for livestock and poultry as well as preparation method and application thereof | |
| RU2744987C2 (en) | Parenteral compositions and their application | |
| CN111437249B (en) | Compound gentamicin sulfate injection and preparation method and application thereof | |
| Rassouli et al. | Comparative pharmacokinetics of enrofloxacin after subcutaneous administration of a novel in situ gel forming preparation and a conventional product to rabbits. | |
| CN101416977A (en) | Preparation method of azalide type tulathromvcin injection | |
| CN108404110A (en) | One age in days hatching device spray delivery of poultry aquatic bird purifies medication | |
| CN102755342A (en) | Compound paracetamol injection and preparation method thereof | |
| CN102552888B (en) | Suppository for treating mammal endometritis | |
| Kiani | Ali Rassouli1*, Sakineh Khanamani Falahatipour2, Yalda Hosseinzadeh Ardakani3, Hamid Akbari Javar3 | |
| CN117562857A (en) | Talarmycin ketoprofen injection and preparation method thereof | |
| CN101966186A (en) | Composition for treating chicken escherichia coli infection and preparation method thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C02 | Deemed withdrawal of patent application after publication (patent law 2001) | ||
| WD01 | Invention patent application deemed withdrawn after publication |
Open date: 20090506 |